| scholarly article | Q13442814 |
| P2093 | author name string | Hetal D Shah | |
| Ramesh K Goyal | |||
| Keyur H Parikh | |||
| Ajay M Naik | |||
| Sangeeta Iyer | |||
| Anish H Chandarana | |||
| Hemang A Baxi | |||
| Joyal N Shah | |||
| Milan C Chag | |||
| Urmil G Shah | |||
| Kanan J Shah | |||
| P2860 | cites work | Utility of inflammatory markers in the management of coronary artery disease | Q28196757 |
| Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study | Q28239287 | ||
| Mechanism of action of fibrates on lipid and lipoprotein metabolism | Q28288187 | ||
| Fibrates, dyslipoproteinaemia and cardiovascular disease | Q28370659 | ||
| Fibrates suppress fibrinogen gene expression in rodents via activation of the peroxisome proliferator-activated receptor-alpha | Q28374051 | ||
| Evaluation of methods for the measurement of low-density lipoprotein cholesterol. | Q29547378 | ||
| Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) | Q29547825 | ||
| The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators | Q29547887 | ||
| Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group | Q29619842 | ||
| Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia | Q31804136 | ||
| Do HMG-CoA reductase inhibitors affect fibrinogen? | Q32052986 | ||
| Genetics of inflammation and risk of coronary artery disease: the central role of interleukin-6. | Q34033682 | ||
| Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study) | Q34461279 | ||
| Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia | Q34820339 | ||
| Evolution and organization of the fibrinogen locus on chromosome 4: gene duplication accompanied by transposition and inversion | Q36423175 | ||
| Control of plasma fibrinogen levels | Q38737722 | ||
| Fibrinogen and cardiovascular risk. | Q40429656 | ||
| Effect of fenofibrate on serum inflammatory markers in patients with high triglyceride values | Q40516350 | ||
| Therapeutic interventions to lower plasma fibrinogen concentration | Q40553954 | ||
| Bezafibrate down-regulates fibrinogen biosynthesis in human hepatoma HepG2 cells | Q41051564 | ||
| Statins: within-group comparisons, statin escape and combination therapy. | Q41443447 | ||
| Pharmacological approaches and strategies for therapeutic modulation of fibrinogen | Q41560071 | ||
| Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia | Q41731971 | ||
| Regulation of fibrinogen assembly. Transfection of Hep G2 cells with B beta cDNA specifically enhances synthesis of the three component chains of fibrinogen. | Q41737070 | ||
| A pharmacoepidemiological assessment of the effect of statins and fibrates on fibrinogen concentration | Q43833293 | ||
| Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia | Q44043336 | ||
| Hemostatic effects of atorvastatin versus simvastatin | Q44378136 | ||
| Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome | Q44397618 | ||
| Comparative effects of simvastatin and atorvastatin in hypercholesterolemic patients with characteristics of metabolic syndrome | Q44513021 | ||
| Effects of atorvastatin (10 mg) on hemostatic and inflammatory parameters in hyperlipidemic patients with angiographically proven coronary artery disease | Q44972887 | ||
| Atorvastatin reduces fibrinogen levels in patients with severe hypercholesterolemia: additional evidence to support the anti-inflammatory effects of statins | Q45028530 | ||
| The comparison of simvastatin and atorvastatin effects on hemostatic parameters in patients with hyperlipidemia type II | Q46702485 | ||
| Antiatherothrombotic properties of statins: implications for cardiovascular event reduction | Q48011361 | ||
| Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. | Q51679983 | ||
| Comparison of the efficacy of atorvastatin and micronized fenofibrate in the treatment of mixed hyperlipidemia. | Q53931120 | ||
| Association of Fibrinogen With Cardiovascular Risk Factors and Cardiovascular Disease in the Framingham Offspring Population | Q59608089 | ||
| Overall and coronary heart disease mortality rates in relation to major risk factors in 325,348 men screened for the MRFIT. Multiple Risk Factor Intervention Trial | Q68906440 | ||
| [The effect of micronized fenofibrate on lipid parameters and fibrinogen in heterozygous familial hypercholesterolemia and familial combined hyperlipidemia] | Q71792372 | ||
| Blood rheology, cardiovascular risk factors, and cardiovascular disease: the West of Scotland Coronary Prevention Study | Q73139390 | ||
| An assessment of the efficacy of atorvastatin in achieving LDL cholesterol target levels in patients with coronary heart disease: a general practice study | Q73326589 | ||
| Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia | Q73691630 | ||
| Inhibition of HMG-CoA reductase by atorvastatin decreases both VLDL and LDL apolipoprotein B production in miniature pigs | Q73965757 | ||
| Influence of atorvastatin versus simvastatin on fibrinogen and other hemorheological parameters in patients with severe hypercholesterolemia treated with regular low-density lipoprotein immunoadsorption apheresis | Q74052185 | ||
| Effect of atorvastatin on plasma fibrinogen | Q74282353 | ||
| [Rapid physiological coagulation method in determination of fibrinogen] | Q74515389 | ||
| Effects of high doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I | Q77769386 | ||
| Inhibition of proinflammatory cytokine production by pravastatin | Q78165454 | ||
| Fenofibrate decreases plasma fibrinogen, improves lipid profile, and reduces uricemia | Q78165927 | ||
| Effect of Atorvastatin versus Simvastatin on Lipid Profile and Plasma Fibrinogen in Patients with Hypercholesterolaemia: A Pilot, Randomised, Double-Blind, Dose-Titrating Study | Q80967325 | ||
| P433 | issue | 2 | |
| P921 | main subject | acute coronary syndrome | Q266018 |
| statin therapy | Q62562875 | ||
| P304 | page(s) | 91-96 | |
| P577 | publication date | 2007-01-01 | |
| P1433 | published in | Experimental & Clinical Cardiology | Q5421099 |
| P1476 | title | Beneficial effects of the addition of fenofibrate to statin therapy in patients with acute coronary syndrome after percutaneous coronary interventions | |
| P478 | volume | 12 |
| Q37653029 | Fenofibrate/simvastatin fixed-dose combination in the treatment of mixed dyslipidemia: safety, efficacy, and place in therapy | cites work | P2860 |
Search more.